Internal Medicine, Hematology & Oncology · Minneapolis, MN
NPI
1174569354
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
5
Medicare group memberships
Hospitals
5
Hospital affiliations
M Health Center for Bleeding and Clotting Disorders, 2512 S 7th St, Suite 105
Minneapolis, MN, 55454
Phone (612) 273-5005
Groups this clinician bills Medicare through
Medicare paid, 2024
$11K
147 services
Medicare patients, 2024
92
Average age 64
Drug cost, 2024
$1.5M
571 prescriptions
Company payments, 2025
$32K
From 5 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Marshall A Mazepa was code 99214 (office e&m - established), 19 times for 15 patients. In total Marshall A Mazepa billed 147 services in 17 codes, and Medicare paid $11K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-06-14.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 19 | 15 | $63.98 | $1,216 |
| 99222 Hospital E&M - Initial | Facility | 16 | 14 | $97.48 | $1,560 |
| 99223 Hospital E&M - Initial | Facility | 14 | 14 | $129.99 | $1,820 |
| 99213 Office E&M - Established | Office | 13 | 13 | $66.42 | $863 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 11 | 11 | $12.54 | $138 |
By year: 2022 $13K for 142 services; 2023 $11K for 131 services; 2024 $11K for 147 services.
Medicare prescription drug claims, 2024
In 2024, the drug Marshall A Mazepa prescribed most often to Medicare patients was Eliquis (Apixaban), with 131 prescriptions and refills. In total Marshall A Mazepa wrote 571 Medicare prescriptions that cost $1.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eliquis Apixaban | 131 | 165 | 25 | $94K |
| Xarelto Rivaroxaban | 100 | 115 | 14 | $65K |
| Oxycodone Hcl Generic | 44 | 44 | Under 11 | $1,085 |
| Tranexamic Acid Generic | 25 | 25 | Under 11 | $8,082 |
| Warfarin Sodium Generic | 21 | 31 | Under 11 | $82.23 |
| Methocarbamol Generic | 16 | 16 | Under 11 | $65.55 |
| Jakafi Ruxolitinib Phosphate | 13 | 13 | Under 11 | $109K |
| Hydroxyzine Hcl Generic | 13 | 13 | Under 11 | $34.39 |
| Empaveli Pegcetacoplan | 13 | 13 | Under 11 | $690K |
| Tizanidine Hcl Generic | 12 | 12 | Under 11 | $0.6 |
| Sprycel Dasatinib | 12 | 12 | Under 11 | $209K |
| Cyclosporine Modified Cyclosporine, Modified | 12 | 12 | Under 11 | $1,407 |
| Promacta Eltrombopag Olamine | 11 | 11 | Under 11 | $85K |
| Fondaparinux Sodium Generic | 11 | 11 | Under 11 | $14K |
| Ibuprofen Generic | 11 | 11 | Under 11 | $4.19 |
Brand drugs: 318 claims; generic drugs: 253 claims; opioid claims: 54.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Marshall A Mazepa $32K ($6,901 in general payments such as food, travel and fees and $25K for research) from 5 companies. The largest payer was HEMA Biologics, LLC with $25K.
| Company | Payments | Amount |
|---|---|---|
| HEMA Biologics, LLC | 5 | $25K |
| Novartis Pharmaceuticals Corporation NVS | 2 | $6,901 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.